News

pharmaphorum10m
Hengrui to file obesity shot in China after phase 3 win
Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...
Dagens.com on MSN56m
Popular GLP-1 Treatment Has an Unexpected Bonus for Men
When it comes to medications like Ozempic, the focus is usually on weight loss. However, a recent study from SSM Health St.